Stage IV Colorectal Cancer Clinical Trial
Official title:
Use of Dignity Therapy in Stage IV Colorectal Cancer Patients Receiving Chemotherapy to Increase Peaceful Awareness and Impact Goals of Care Decision-Making
Verified date | September 2013 |
Source | Northwestern University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to try and improve the way that patients with colon cancer understand and cope with their illness and give them tools for talking with their loved ones and family about their illness.
Status | Completed |
Enrollment | 24 |
Est. completion date | October 2012 |
Est. primary completion date | May 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
- Participants must be currently receiving treatment for stage IV colorectal cancer. - Participants must have experience disease progression after their first course of treatment and are being considered for second course of treatment or have already started their second course of treatment. - Participants must be 18 years old or older. - All participants must have given signed, informed consent prior to registration on study. - Participants must speak English. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University, Northwestern Memorial Faculty Foundation | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Northwestern University | Robert H. Lurie Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Impact of Dignity Therapy | Measure the impact of dignity therapy on terminal illness acknowledgment and presence of peaceful awareness. Subjects will complete self-evaluation questionnaires at the point of registration and upon completing dignity therapy sessions. The impact will be determined by changes in the patient's baseline self-reported parameters. | at baseline, 1-2 weeks after completion of dignity therapy sessions, 1 month after completion of sessions | No |
Secondary | Measure the impact of dignity therapy on life sustaining therapy and end-of-life goals of care. | Subjects will complete self-evaluation questionnaires at the point of registration and upon completing dignity therapy sessions. The impact will be determined by changes in the patient's baseline self-reported parameters. | at baseline, 1-2 weeks after completion of dignity therapy sessions, 1 month after completion of dignity therapy sessions | No |
Secondary | Establish a correlation between terminal illness acknowledgement and presence of peaceful awareness with preferences for life sustaining therapy and end-of-life goals of care. | Establish a correlation between terminal illness acknowledgement and presence of peaceful awareness with preferences for life sustaining therapy and end-of-life goals of care. | At Study Completion | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01704703 -
Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
|
Phase 2 | |
Terminated |
NCT02960282 -
Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
|
||
Completed |
NCT01998152 -
Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT)
|
N/A | |
Not yet recruiting |
NCT06287723 -
French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
|
||
Completed |
NCT03005002 -
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
|
Phase 1 | |
Completed |
NCT03095781 -
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
|
Phase 1 | |
Terminated |
NCT03111823 -
Exercise Program During Chemotherapy in Metastatic Colorectal Cancer
|
N/A | |
Active, not recruiting |
NCT04267575 -
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
|
N/A | |
Recruiting |
NCT03368963 -
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
Active, not recruiting |
NCT01271582 -
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
|
Phase 4 | |
Active, not recruiting |
NCT03800602 -
Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT05631574 -
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
|
Phase 1 | |
Completed |
NCT03112668 -
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
|
N/A | |
Terminated |
NCT01550510 -
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
|
Phase 1/Phase 2 | |
Recruiting |
NCT02919644 -
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.
|
Phase 2 | |
Completed |
NCT03373188 -
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
|
Phase 1 | |
Terminated |
NCT04044430 -
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
|
Phase 1 | |
Completed |
NCT05025748 -
Ask Questions (ASQ):Implementation of a Communication Intervention
|
N/A | |
Completed |
NCT01722903 -
Detection of CTCs in Patients Undergoing Surgery for Stage IV Colorectal Cancer
|
N/A |